Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07634432 · ClinicalTrials.gov registry record · NA
Bridges: A Digital Intervention to Increase Workplace Belonging
A NA study, sponsored by Pro-Change Behavior Systems.
- Completed
- Registry status
- NA
- Development phase
- 136
- Enrollment target
NCT07634432: Completed NA study, sponsored by Pro-Change Behavior Systems.
NCT07634432 is a NA study that has completed, run by Pro-Change Behavior Systems. The registered enrollment target is 136 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07634432, a NA study, has completed, sponsored by Pro-Change Behavior Systems.
- COMPLETED
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate Bridges, a digital program designed to support workplace belonging among LGBTQ+ employees. Belonging is an important part of health and well-being. People who feel accepted, valued, connected, and included often experience better mental and physical health. However, many LGBTQ+ individuals experience discrimination, stigma, exclusion, or isolation in workplace settings, which can negatively affect their sense of belonging and overall well-being. Bridges was developed to help LGBTQ+ employees build a stronger sense of belonging at work. The program combines personalized text messages with online activities, self-reflection exercises, practical workplace strategies, and opportunities to learn skills that may support connection, inclusion, and well-being. This study will enroll LGBTQ+ adults who are currently employed. Participants will use the Bridges program for approximately 30 days. During the study, participants will receive text messages and have access to online tools and activities. Participants will also complete surveys to assess their experiences, sense of workplace belonging, and feedback about the program. The primary purpose of this pilot study is to determine whether the Bridges program is feasible and acceptable to participants. Researchers will examine participant engagement with the program and satisfaction with its content and usability. The study will also explore whether participation in Bridges is associated with improvements in workplace belonging, well-being, and related outcomes. Information gathered from this study will be used to improve the program and guide future research on digital interventions designed to support belonging and well-being among LGBTQ+ employees.
Primary Outcome
Proportion of participants who continued receiving text messages throughout the intervention period. Range is 0-100, with 100% indicating everyone continued receiving messages.
Interventions
- BEHAVIORAL Bridges
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-08-14 |
| Est. Completion | 2025-11-22 |
| Phase | NA |
What the finished NCT07634432 record still lists
NCT07634432 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Bridges is the first listed.
NCT07634432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07634432 about?
NCT07634432 is a clinical study titled "Bridges: A Digital Intervention to Increase Workplace Belonging". The purpose of this study is to evaluate Bridges, a digital program designed to support workplace belonging among LGBTQ+ employees. Belonging is an important part of health and well-being. People who feel accepted, valued, connected, and included often experience better mental and physical health. ...
What is the current status of trial NCT07634432?
This trial is currently completed. It is a NA study. The enrollment target is 136 participants. The study started on 2025-08-14. Estimated completion is 2025-11-22.
What interventions are being tested in trial NCT07634432?
The interventions under investigation include: Bridges (BEHAVIORAL).
Who is sponsoring clinical trial NCT07634432?
This trial is sponsored by Pro-Change Behavior Systems, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07634432's enrollment target sits among peer trials
136 722nd of 2000 higher than 1,275 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI